Alto Neuroscience, Inc. (ANRO)

USD 2.08

(-2.35%)

Net Debt Summary of Alto Neuroscience, Inc.

  • Alto Neuroscience, Inc.'s latest annual net debt in 2023 was 68.91 Million USD , up 104.12% from previous year.
  • Alto Neuroscience, Inc.'s latest quarterly net debt in 2024 Q2 was -183.06 Million USD , up 6.54% from previous quarter.
  • Alto Neuroscience, Inc. reported annual net debt of 33.76 Million USD in 2022, up 171.01% from previous year.
  • Alto Neuroscience, Inc. reported annual net debt of 12.45 Million USD in 2021, down 0.0% from previous year.
  • Alto Neuroscience, Inc. reported quarterly net debt of -195.88 Million USD for 2024 Q1, down -384.24% from previous quarter.
  • Alto Neuroscience, Inc. reported quarterly net debt of 68.91 Million USD for 2023 Q4, up 266.72% from previous quarter.

Annual Net Debt Chart of Alto Neuroscience, Inc. (2023 - 2021)

Historical Annual Net Debt of Alto Neuroscience, Inc. (2023 - 2021)

Year Net Debt Net Debt Growth
2023 68.91 Million USD 104.12%
2022 33.76 Million USD 171.01%
2021 12.45 Million USD 0.0%

Peer Net Debt Comparison of Alto Neuroscience, Inc.

Name Net Debt Net Debt Difference
ADC Therapeutics SA -154.22 Million USD 144.686%
Annovis Bio, Inc. -5.75 Million USD 1297.539%
Biohaven Pharmaceutical Holding Company Ltd. -218.84 Million USD 131.491%
Ginkgo Bioworks Holdings, Inc. -707.09 Million USD 109.746%
Nuvation Bio Inc. -38.64 Million USD 278.342%
Nuvation Bio Inc. -38.64 Million USD 278.342%
Arcus Biosciences, Inc. -116 Million USD 159.409%
Zymeworks Inc. -130.83 Million USD 152.673%